供体急性肾损伤的严重程度会影响肾移植后的预后吗?

IF 1.9 4区 医学 Q2 SURGERY
Alexandra R. Monetti, Christopher J. Webb, Colleen L. Jay, Emily McCracken, Berjesh Sharda, Matthew Garner, Alan C. Farney, Giuseppe Orlando, Amber Reeves-Daniel, Alejandra Mena-Gutierrez, Natalia Sakhovskaya, Robert J. Stratta
{"title":"供体急性肾损伤的严重程度会影响肾移植后的预后吗?","authors":"Alexandra R. Monetti,&nbsp;Christopher J. Webb,&nbsp;Colleen L. Jay,&nbsp;Emily McCracken,&nbsp;Berjesh Sharda,&nbsp;Matthew Garner,&nbsp;Alan C. Farney,&nbsp;Giuseppe Orlando,&nbsp;Amber Reeves-Daniel,&nbsp;Alejandra Mena-Gutierrez,&nbsp;Natalia Sakhovskaya,&nbsp;Robert J. Stratta","doi":"10.1111/ctr.15425","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Introduction</h3>\n \n <p>The study purpose was to review retrospectively our single-center experience transplanting kidneys from deceased donors (DD) with acute kidney injury (AKI) according to terminal serum creatinine (tSCr) level.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>AKI kidneys were defined by a doubling of the DD's admission SCr and a tSCr ≥ 2.0 mg/dL.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>From 1/07 to 11/21, we transplanted 236 AKI DD kidneys, including 100 with a tSCr ≥ 3.0 mg/dL (high SCr AKI group, mean tSCr 4.2 mg/dL), and the remaining 136 from DDs with a tSCr of 2.0–2.99 mg/dL (lower SCr AKI group, mean tSCr 2.4 mg/dL). These two AKI groups were compared to 996 concurrent control patients receiving DD kidneys with a tSCr &lt; 1.0 mg/dL. Mean follow-up was 69 months. Delayed graft function (DGF) rates were 51% versus 46% versus 29% (<i>p</i> &lt; 0.0001), and 5-year patient and death-censored kidney graft survival rates were 96.8% versus 83.5% versus 82.2% (<i>p</i> = 0.002) and 86.7% versus 77.8% versus 78.8% (<i>p</i> = 0.18) in the high tSCr AKI versus lower tSCr AKI versus control groups, respectively.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Despite a higher incidence of DGF, patients receiving kidneys from DDs with tSCr levels ≥3.0 mg/dL have acceptable medium-term outcomes compared to either AKI DDs with a lower tSCr or DDs with a tSCr &lt; 1.0 mg/dL.</p>\n </section>\n </div>","PeriodicalId":10467,"journal":{"name":"Clinical Transplantation","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Does Severity of Donor Acute Kidney Injury Influence Outcomes Following Kidney Transplantation?\",\"authors\":\"Alexandra R. Monetti,&nbsp;Christopher J. Webb,&nbsp;Colleen L. Jay,&nbsp;Emily McCracken,&nbsp;Berjesh Sharda,&nbsp;Matthew Garner,&nbsp;Alan C. Farney,&nbsp;Giuseppe Orlando,&nbsp;Amber Reeves-Daniel,&nbsp;Alejandra Mena-Gutierrez,&nbsp;Natalia Sakhovskaya,&nbsp;Robert J. Stratta\",\"doi\":\"10.1111/ctr.15425\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Introduction</h3>\\n \\n <p>The study purpose was to review retrospectively our single-center experience transplanting kidneys from deceased donors (DD) with acute kidney injury (AKI) according to terminal serum creatinine (tSCr) level.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>AKI kidneys were defined by a doubling of the DD's admission SCr and a tSCr ≥ 2.0 mg/dL.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>From 1/07 to 11/21, we transplanted 236 AKI DD kidneys, including 100 with a tSCr ≥ 3.0 mg/dL (high SCr AKI group, mean tSCr 4.2 mg/dL), and the remaining 136 from DDs with a tSCr of 2.0–2.99 mg/dL (lower SCr AKI group, mean tSCr 2.4 mg/dL). These two AKI groups were compared to 996 concurrent control patients receiving DD kidneys with a tSCr &lt; 1.0 mg/dL. Mean follow-up was 69 months. Delayed graft function (DGF) rates were 51% versus 46% versus 29% (<i>p</i> &lt; 0.0001), and 5-year patient and death-censored kidney graft survival rates were 96.8% versus 83.5% versus 82.2% (<i>p</i> = 0.002) and 86.7% versus 77.8% versus 78.8% (<i>p</i> = 0.18) in the high tSCr AKI versus lower tSCr AKI versus control groups, respectively.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusions</h3>\\n \\n <p>Despite a higher incidence of DGF, patients receiving kidneys from DDs with tSCr levels ≥3.0 mg/dL have acceptable medium-term outcomes compared to either AKI DDs with a lower tSCr or DDs with a tSCr &lt; 1.0 mg/dL.</p>\\n </section>\\n </div>\",\"PeriodicalId\":10467,\"journal\":{\"name\":\"Clinical Transplantation\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2024-08-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Transplantation\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/ctr.15425\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"SURGERY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Transplantation","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/ctr.15425","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"SURGERY","Score":null,"Total":0}
引用次数: 0

摘要

简介:研究目的是根据终末血清肌酐(tSCr)水平回顾性回顾我们单中心移植急性肾损伤(AKI)已故供体(DD)肾脏的经验:AKI肾脏的定义是DD入院SCr增加一倍且tSCr≥2.0 mg/dL:从2007年1月1日到2011年11月21日,我们移植了236个AKI DD肾脏,其中100个tSCr≥3.0 mg/dL(高SCr AKI组,平均tSCr为4.2 mg/dL),其余136个来自tSCr为2.0-2.99 mg/dL的DD(低SCr AKI组,平均tSCr为2.4 mg/dL)。这两组 AKI 患者与同时接受 DD 肾脏且 tSCr < 1.0 mg/dL 的 996 名对照组患者进行了比较。平均随访时间为 69 个月。在高tSCr AKI组与低tSCr AKI组和对照组中,移植功能延迟(DGF)率分别为51%对46%对29%(p < 0.0001),5年患者和死亡剪除肾脏移植存活率分别为96.8%对83.5%对82.2%(p = 0.002)和86.7%对77.8%对78.8%(p = 0.18):结论:尽管DGF的发生率较高,但与tSCr水平≥3.0 mg/dL的AKI DD或tSCr<1.0 mg/dL的DD相比,接受tSCr水平≥3.0 mg/dL的DD肾脏的患者的中期预后是可以接受的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Does Severity of Donor Acute Kidney Injury Influence Outcomes Following Kidney Transplantation?

Introduction

The study purpose was to review retrospectively our single-center experience transplanting kidneys from deceased donors (DD) with acute kidney injury (AKI) according to terminal serum creatinine (tSCr) level.

Methods

AKI kidneys were defined by a doubling of the DD's admission SCr and a tSCr ≥ 2.0 mg/dL.

Results

From 1/07 to 11/21, we transplanted 236 AKI DD kidneys, including 100 with a tSCr ≥ 3.0 mg/dL (high SCr AKI group, mean tSCr 4.2 mg/dL), and the remaining 136 from DDs with a tSCr of 2.0–2.99 mg/dL (lower SCr AKI group, mean tSCr 2.4 mg/dL). These two AKI groups were compared to 996 concurrent control patients receiving DD kidneys with a tSCr < 1.0 mg/dL. Mean follow-up was 69 months. Delayed graft function (DGF) rates were 51% versus 46% versus 29% (p < 0.0001), and 5-year patient and death-censored kidney graft survival rates were 96.8% versus 83.5% versus 82.2% (p = 0.002) and 86.7% versus 77.8% versus 78.8% (p = 0.18) in the high tSCr AKI versus lower tSCr AKI versus control groups, respectively.

Conclusions

Despite a higher incidence of DGF, patients receiving kidneys from DDs with tSCr levels ≥3.0 mg/dL have acceptable medium-term outcomes compared to either AKI DDs with a lower tSCr or DDs with a tSCr < 1.0 mg/dL.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Clinical Transplantation
Clinical Transplantation 医学-外科
CiteScore
3.70
自引率
4.80%
发文量
286
审稿时长
2 months
期刊介绍: Clinical Transplantation: The Journal of Clinical and Translational Research aims to serve as a channel of rapid communication for all those involved in the care of patients who require, or have had, organ or tissue transplants, including: kidney, intestine, liver, pancreas, islets, heart, heart valves, lung, bone marrow, cornea, skin, bone, and cartilage, viable or stored. Published monthly, Clinical Transplantation’s scope is focused on the complete spectrum of present transplant therapies, as well as also those that are experimental or may become possible in future. Topics include: Immunology and immunosuppression; Patient preparation; Social, ethical, and psychological issues; Complications, short- and long-term results; Artificial organs; Donation and preservation of organ and tissue; Translational studies; Advances in tissue typing; Updates on transplant pathology;. Clinical and translational studies are particularly welcome, as well as focused reviews. Full-length papers and short communications are invited. Clinical reviews are encouraged, as well as seminal papers in basic science which might lead to immediate clinical application. Prominence is regularly given to the results of cooperative surveys conducted by the organ and tissue transplant registries. Clinical Transplantation: The Journal of Clinical and Translational Research is essential reading for clinicians and researchers in the diverse field of transplantation: surgeons; clinical immunologists; cryobiologists; hematologists; gastroenterologists; hepatologists; pulmonologists; nephrologists; cardiologists; and endocrinologists. It will also be of interest to sociologists, psychologists, research workers, and to all health professionals whose combined efforts will improve the prognosis of transplant recipients.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信